Genetics of IL6 polymorphisms: Case–control study of the risk of endometrial cancer

Cai, Junhong; Cui, Kaiying; Niu, Fanglin; Jin, Tianbo; Huang, Sizhe; Zhang, Ying; Bao, Shaowen

doi:10.1002/mgg3.600

Cited by 5 publications

(5 citation statements)

References 27 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, the levels of IL‐6 mRNA and protein were increased in EC patients. This finding was in concordance with research suggesting that IL‐6 is upregulated in endometrioid adenocarcinoma 36 . Other studies have provided evidence that elevated levels of IL‐6 significantly increase the risk of EC 14,37 .…”

Section: Discussionsupporting

confidence: 91%

“…This finding was in concordance with research suggesting that IL-6 is upregulated in endometrioid adenocarcinoma. 36 Other studies have provided evidence that elevated levels of IL-6 significantly increase the risk of EC. 14,37 Che et al 37 demonstrated the existence of an autocrine positive feedback loop in which IL-6 promotes EC cell proliferation that stimulates its production through the ERK-NF-κB pathway.…”

Section: The Association Between Inflammatory Cytokines and Microbimentioning

confidence: 99%

See 1 more Smart Citation

Dysbiosis of the endometrial microbiota and its association with inflammatory cytokines in endometrial cancer

Lin

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

The underlying molecular mechanisms involved in the pathogenesis of endometrial cancer (EC) are still not well understood. Our goal was to investigate the composition of the endometrial microbiota and the association with inflammatory cytokines in EC. Endometrial microbiota profiles of women with EC (n = 25) and benign uterine lesions (BUL, n = 25) were assessed by 16S ribosomal RNA gene amplicon sequencing. The expression levels of interleukin‐6 (IL‐6), interleukin‐8 (IL‐8), and interleukin‐17 (IL‐17) mRNA and protein in the endometrial tissues of the two groups were determined by real‐time quantitative polymerase chain reaction and Western blot, respectively. There were significant differences in alpha diversity based on the observed operational taxonomic units (P = .002), Pielou evenness (P = .001), and Shannon index (P < .001) between EC and BUL groups. Significant differences were also found in Bray‐Curtis (P = .001) and unweighted UniFrac (P = .001) beta diversity measures between the two groups. At the genus level, Micrococcus was more abundant in the EC group. Pseudoramibacter_Eubacterium, Rhodobacter, Vogesella, Bilophila, Rheinheimera, and Megamonas were enriched in the BUL group. There were no differences in IL‐8 and IL‐17 protein levels between the two groups, except IL‐6 protein levels. However, the mRNA expression levels of IL‐6, IL‐8, and IL‐17 were significantly different. Moreover, the relative abundances of Micrococcus was positively correlated with IL‐6, and IL‐17 mRNA levels. In conclusion, our results suggested that dysbiosis of endometrial microbiota and the inflammatory cytokines were associated with Micrococcus in EC patients, which might be useful for exploration of the mechanism between the endometrial microbiota and inflammatory responses in future studies.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: The Association Between Inflammatory Cytokines and Microbimentioning

confidence: 99%

Dysbiosis of the endometrial microbiota and its association with inflammatory cytokines in endometrial cancer

Lin

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Five polymorphisms of IL-6 were studied as rs1800796, rs2069837, rs1524107, rs2066992, rs2069840. Among these SNPs, rs1524107, and rs2066992 were identified to have association with EC risk (Cai et al, 2019)…”

Section: Interleukin-6 Gene Polymorphismsmentioning

confidence: 99%

Interleukins (IL-1A and IL-6) and the risk of Endometrial Carcinoma

Ramadan

Hemida

Mehanna

et al. 2022

Records of Pharmaceutical and Biomedical Sciences

View full text Add to dashboard Cite

Endometrial carcinoma (EC) is a cancer that develops in the uterine or womb lining (Endometrium). It is the outcome of cells that have the capacity to move to other parts of the body growing abnormally. Hereditary causes account for 2-10% of all EC cases. Endometrial carcinoma develops as natural endometrial cell development is disrupted, new cells form unnecessarily, and old or weakened cells do not die when they should. The buildup of extra cells sometimes results in the formation of a mass of tissue known as a growth or tumor. This abnormal cancer cells have a number of genetic abnormalities that allow them to proliferate uncontrollably. Interleukins (ILs) are a subset of a larger group of cellular messenger molecules called cytokines, which are modulators of cellular behavior. Interleukins have role in therapeutics as well as diagnosis and prognosis as biomarker in various conditions. Additionally, it has been proposed that genetic polymorphisms in functionally important genes may be risk factors for the development of a number of malignancies, including endometrial cancer. This review pays attention to understand the risk of EC, and the importance of the effect of gene polymorphism (IL-6 rs1800795, and IL-1A rs1800587) on it. Also, their involvement in the etiology, pathogenesis, and outcome of the disease are explained, aiming to provide new insights into the pathogenesis of EC and the possibility to develop novel therapeutic approaches through targeting these genes.

show abstract

“…The single nucleotide polymorphism (SNP) is the most common form of human genetic variations, which are significantly linked to the risk of tumorigenesis. It was reported that the polymorphisms in rs3783553, rs3783550, rs3783546, rs1609682 and rs3783521 of IL-1α ( 138 , 139 ), rs1524107 and rs2066992 of IL-6 ( 140 ), rs4758680 and rs7977932 of IL-31 ( 141 ), rs28372698 and rs12934561 of IL-32 ( 2 ) may be relevant to increased susceptibility to EC in Chinese women. Moreover, the CC genotype of IL-6 Gene (−174 & -572) might contribute to EC risk ( 142 ).…”

Section: Clinical Application Of Interleukins In Ecmentioning

confidence: 99%

The roles and clinical applications of interleukins in endometrial carcinoma

Zang

Liu

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

As a common malignant tumor of the female reproductive system, endometrial carcinoma (EC) seriously endangers women’s health with an increasing incidence. The oncogenesis and progression of cancer are closely linked with immune microenvironment, of which interleukins are the important components. In order to illustrate the roles and clinical applications of interleukins in EC, literature of interleukins and EC were reviewed. Based on the present studies, interleukins play crucial roles in the oncogenesis and development of EC via regulating the proliferation, migration, invasion, angiogenesis, apoptosis, pyroptosis and autophagy of EC as well as the immune function against EC. And some of the interleukins seems to have prospective clinical applications in EC, such as evaluating the risk of tumorigenesis, discriminating the malignancy from benign disorders or normal condition, indicating cancer aggressiveness, predicting the prognosis of patients and serving as the novel therapy. However, there is still a long way to go before the clinical applications of interleukins in EC come into reality. Nevertheless, it is certain that the exploration of interleukins will definitely be of great benefit to the screening, diagnosis and treatment of EC in the future.

show abstract

Genetics of IL6 polymorphisms: Case–control study of the risk of endometrial cancer

Cited by 5 publications

References 27 publications

Dysbiosis of the endometrial microbiota and its association with inflammatory cytokines in endometrial cancer

Dysbiosis of the endometrial microbiota and its association with inflammatory cytokines in endometrial cancer

Interleukins (IL-1A and IL-6) and the risk of Endometrial Carcinoma

The roles and clinical applications of interleukins in endometrial carcinoma

Contact Info

Product

Resources

About